Safety of sodium‐glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
Pooled result · Acute kidney injuryResult — go to the resultRelative risk 0.73 95% CI 0.62–0.87Authors' conclusion
SGLT2is were well tolerated in the elderly. However, older patients are underrepresented in most RCTs and a call for action is need to favour clinical trials reporting safety outcomes stratified by age.
Study context
- Population
- Elderly (≥65 years) patients with T2D in randomized controlled trials (RCTs) reporting safety outcomes
- Participants
- 19,986 elderly6 RCTs
- Comparison
- SGLT2i vs placebo
- Outcome
- Acute kidney injury
Pooled result
As reported in the abstract
Relative risk
0.73
95% CI 0.62–0.87
SGLT2ivs Placebo
RR 0.73 (95% CI 0.62–0.87)
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| Genital tract infectionsSix-fold increased risk with SGLT2i | 6.55 (2.09–20.5) | |
| AmputationsCanagliflozinvs PlaceboIncreased only among canagliflozin users | 1.94 (1.25–3) | |
| 0.050.21520Relative risk (log scale) |
Drug discontinuation
- SGLT2i discontinuation rate
- ≈20%
Fractures, UTI, volume depletion, hypoglycaemia, DKA
- Risk similar between SGLT2i and placebo
Original publication
Safety of sodium‐glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta‐analysis of randomized controlled trials. Diabetes Obes Metab. Published 4 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →